Adverse Events Seen With Combination Lenvatinib and Pembrolizumab for Recurrent Endometrial Cancer

Commentary
Video

Kimberly A. Spickes, CNP, details the adverse events she sees with combination lenvatinib and pembrolizumab treatment for recurrent endometrial cancer.

Recent Videos
Gynecologic Cancers
Related Content
gynecologic system with cancerous tumor

Sacituzumab Tirumotecan Shows Promise in Pretreated Gynecologic Cancer

Ashley Chan
November 18th 2024
Article

Sacituzumab tirumotecan had antitumor activity in pretreated advanced endometrial and ovarian cancer, data showed.

The Vitals

Lauren Mahon Offers Nurse Perspectives on PARP Inhibitors As Ovarian Cancer Maintenance Therapy

Lindsay Fischer
June 15th 2023
Podcast

Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.

clinician in white coat holding a board that says "cervical cancer"

Adding Cancer Vaccine to Avelumab Doesn’t Boost PFS in Gynecologic Cancer

Russ Conroy
October 16th 2024
Article

The addition of T4001, an investigation cancer vaccine, to avelumab did not improve progression-free survival vs avelumab alone in cervical and anogenital tumors.

Oncology Nursing News

A Look Back at 2022 FDA Approvals in Oncology

Oncology Nursing News
January 2nd 2023
Podcast

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

gynecologic system

WHO Updates Cervical Cancer Prevention Guidelines

Chris Ryan
October 8th 2024
Article

The World Health Organization updated their guidelines to include CINtec PLUS Cytology for gynecologic cancer prevention.

gynecologic cancer

Dato-DXd Seems Safe, Efficacious in Advanced Gynecologic Cancers

Jason M. Broderick
September 18th 2024
Article

Datopotamab deruxtecan(Dato-DXd) demonstrated antitumor activity in patients with advanced/metastatic ovarian or endometrial cancer who had prior chemotherapy treatment.

© 2024 MJH Life Sciences

All rights reserved.